RHAPSIDO (Remibrutinib) Patent Expiration, LOE Window & CMS Spending

RHAPSIDO (Remibrutinib) by Novartis: FDA Orange Book core substance LOE 2034-11-13 (last listed 2043-01-19), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $4,521 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN218436 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-11-13
Last Listed Patent or Exclusivity Date2043-01-19
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,521 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.